<DOC>
	<DOCNO>NCT01556451</DOCNO>
	<brief_summary>This study evaluate safety , tolerability , immunogenicity ZOSTAVAX™ Korean adult . Approximately 180 herpes zoster history negative subject ≥ 50 year age enrol study . Each subject receive single dose ZOSTAVAX™ . No statistical hypothesis test conduct study .</brief_summary>
	<brief_title>ZOSTAVAX™ Safety Immunogenicity Korean Adults ( V211-034 )</brief_title>
	<detailed_description />
	<mesh_term>Herpes Zoster</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>No fever day vaccination Females negative pregnancy test use acceptable method birth control , postmenopausal Underlying chronic illness must stable History hypersensitivity reaction vaccine component Prior history herpes zoster Prior receipt varicella zoster vaccine Pregnant breastfeeding Have recently receive immunoglobulin blood product autologous blood transfusion Received inactivate live virus vaccine within 4 week prior vaccination , expect receive live virus vaccine duration study Received inactivated vaccine within 7 day prior vaccination , expect receive inactivate vaccine duration study Use immunosuppressive therapy Known suspect immune dysfunction Use nontopical antiviral therapy activity herpes virus Known suspect active untreated tuberculosis</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>